Sarcopenia and diabetes (DM) are independent predictors of poor postoperative outcomes. Limited data exists on the prevalence and impact of both conditions on perioperative outcomes in abdominal surgery patients. We performed a retrospective analysis of patients undergoing abdominal surgery who had abdominal CT imaging within 30 days prior to surgery. Measurements of psoas muscle surface area and attenuation values (in Hounsfield units) were recorded at the most anterior convex part of the lumbar spine corresponding to the level of the L3/L4 vertebrae. Sarcopenia was defined as the lowest sex-specific quartile of psoas muscle density. Composite of complications was determined using ICD-9 coding and included: acute MI, stroke, wound infection, pneumonia, UTI, bacteremia and respiratory failure. Among 343 patients, 85 (24%) met criteria for sarcopenia. Patients with sarcopenia were older, more likely to be Caucasian, had a longer length of hospital stay and had more postoperative complications. In fully adjusted analyses, patients with both DM and sarcopenia had four-fold higher rates of complications compared to those without DM or sarcopenia (Table).

In summary, sarcopenia is associated with higher rates of complications in patients with and without DM; the combination of sarcopenia and DM confers an additional risk of perioperative complications in patients undergoing abdominal surgery.

  No Sarcopenia (n=258) Sarcopenia (n=85) P-value 
Age, years 56.7 ± 15.27 63.5 ± 14.29 0.001 
BMI, kg/m2 27.3 ± 6.68 27.2 ± 7.03 0.64 
Male gender, n (%) 119 (46) 39 (46) 0.97 
Race, n (%)     0.005 
Caucasian 154 (60) 66 (78)   
African American 82 (32) 18 (21)   
Other 20 (8) 1 (1)   
Diabetes status, n (%)     0.06 
No diabetes 202 (78) 58 (68)   
Diabetes 56 (22) 27 (32)  
LOS, median, days (interquartile range) 9 (6, 17) 15 (10, 29) <0.01 
No diabetes, composite complications Odds ratio* (95% CI) 1.0 (Ref) 2.47 (1.31-4.66)  
Diabetes, composite complications Odds ratio* (95% CI) 0.61 (0.3-1.25) 3.68 (1.48-9.19)  
  No Sarcopenia (n=258) Sarcopenia (n=85) P-value 
Age, years 56.7 ± 15.27 63.5 ± 14.29 0.001 
BMI, kg/m2 27.3 ± 6.68 27.2 ± 7.03 0.64 
Male gender, n (%) 119 (46) 39 (46) 0.97 
Race, n (%)     0.005 
Caucasian 154 (60) 66 (78)   
African American 82 (32) 18 (21)   
Other 20 (8) 1 (1)   
Diabetes status, n (%)     0.06 
No diabetes 202 (78) 58 (68)   
Diabetes 56 (22) 27 (32)  
LOS, median, days (interquartile range) 9 (6, 17) 15 (10, 29) <0.01 
No diabetes, composite complications Odds ratio* (95% CI) 1.0 (Ref) 2.47 (1.31-4.66)  
Diabetes, composite complications Odds ratio* (95% CI) 0.61 (0.3-1.25) 3.68 (1.48-9.19)  

*Odds ratio of composite of complication adjusted for age, gender, BMI and race

Disclosure

G. Davis: None. M. Fayfman: None. A. Singer: None. M. Umpierrez: None. A. Kakarala: None. L. Peng: None. S. Nair: None. F.J. Pasquel: Consultant; Self; Merck Sharp & Dohme Corp., Sanofi, Boehringer Ingelheim Pharmaceuticals, Inc. G.E. Umpierrez: Research Support; Self; Sanofi US, Merck & Co., Inc., Novo Nordisk Inc., AstraZeneca. Advisory Panel; Self; Sanofi, Intarcia Therapeutics, Inc..

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.